Monopar Therapeutics Inc. (MNPR)
- Previous Close
39.42 - Open
40.20 - Bid 39.82 x 100
- Ask 40.97 x 100
- Day's Range
40.20 - 40.20 - 52 Week Range
1.72 - 54.30 - Volume
744 - Avg. Volume
29,861 - Market Cap (intraday)
245.831M - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-- - EPS (TTM)
-4.11 - Earnings Date May 12, 2025 - May 22, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
58.69
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
www.monopartx.comRecent News: MNPR
View More
Performance Overview: MNPR
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNPR
View MoreValuation Measures
Market Cap
241.06M
Enterprise Value
233.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.87%
Return on Equity (ttm)
-51.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.59M
Diluted EPS (ttm)
-4.11
Balance Sheet and Cash Flow
Total Cash (mrq)
60.21M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.48M